Relapse Patterns From Long-Term Subgroup Analysis of IMpower010

By: Joshua D. Madera, MD
Posted: Monday, October 28, 2024

For select patients with non–small cell lung cancer (NSCLC), IMpower010 met its primary endpoint of significant improvement in disease-free survival with the adjuvant use of the monoclonal antibody atezolizumab vs best supportive care. Now, based on a 5-year subgroup analysis from this trial on relapse patterns, presented at the International Association for the Study of Lung Cancer (IASLC) 2024 World Conference on Lung Cancer (WCLC; Abstract OA01.04), the continued benefit of atezolizumab was reported in certain patients. In addition, distant and central nervous system relapse rates were better with atezolizumab in the tumor cell ≥ 50% population, explained Enriqueta Felip, MD, PhD, of Vall d’Hebron University Hospital, Barcelona, and colleagues, although the patient numbers were small.

In the tumor cell > 1% patient population, the disease-free survival hazard ratios for stage II and IIIA disease were 0.77 and 0.66, respectively. In the tumor cell > 50% patient population, the disease-free survival hazard ratios for stage II and stage IIIA disease were 0.57 and 0.42, respectively. Disease-free survival hazard ratios for regional lymph node status for the tumor cell > 1% and tumor cell > 50% populations were 0.82 and 0.89 for status N0, 0.65 and 0.40 for status pN1, and 0.74 and 0.42 for status pN2, respectively. Similar trends were seen for the overall survival hazard ratios for stage II disease, stage IIIA disease, and regional lymph node status. Furthermore, overall recurrence decreased with the use of atezolizumab in both populations.

A total of 1,005 patients with resected stage II to IIIA NSCLC were recruited for the study. Patients received between one and four postoperative chemotherapy cycles. Following treatment with chemotherapy, patients were randomly assigned to receive treatment with 16 cycles of atezolizumab or best supportive care. Patient populations were further stratified by their PD-L1 tumor cell population.

Disclosure: For full disclosure information, visit wclc2024.iaslc.org.

2024 World Conference on Lung Cancer